---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-032232"
form_type: "8-K"
ticker: "AVTX"
cik: "0001534120"
company_name: "Avalo Therapeutics, Inc."
filed_at: "2025-06-20T23:59:59+00:00"
generated_at: "2026-05-19T01:20:01.151465+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.25
confidence: "medium"
source: SEC EDGAR
---

# Avalo posts updated investor presentation highlighting IL-1β pipeline focus

## Summary
- Presentation dated June 2025 reiterates mission to advance novel IL-1β therapies for unmet medical needs.
- No new clinical data, financial results, or guidance included in the investor deck.
- Company to use presentation in meetings with investors; no material change in strategy disclosed.

## SEC filing metadata
- accession: 0001628280-25-032232
- form_type: 8-K
- ticker: AVTX
- cik: 0001534120
- company_name: Avalo Therapeutics, Inc.
- filed_at: 2025-06-20T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.25
- confidence: medium
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534120/000162828025032232/0001628280-25-032232-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534120/000162828025032232/avtx-20250620.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-032232
- JSON: https://secwatch.observer/filing/0001628280-25-032232.json
- Plain text: https://secwatch.observer/filing/0001628280-25-032232.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.